U.S. Markets closed

Arsanis Shares Soar on Recent Merger Agreement, Analysts Review and Target Price

NEW YORK, NY / ACCESSWIRE / December 3, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Arsanis, Inc. (ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. Arsanis' pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including a respiratory syncytial virus.

A merger announcement involving ASNS sent the company shares soaring from $1.16 on November 26, 2018 to $4.12 per share the next day. The company shares have settled at $3.89 as of the close of Friday's session.

Merger agreement details, combination synergies and more in this full research report READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/arsanis-shares/

The company' shares surged followed by the announcement of a definitive merger agreement, under which X4 Pharmaceuticals is expected to merge with a wholly-owned subsidiary of Arsanis in an all-stock transaction. The merger would result in a combined company operating under the X4 Pharmaceuticals name that will focus on the development and commercialization of X4's lead product candidate, X4P-001, and the advancement of X4's pipeline of treatments for rare diseases of the immune system and rare cancers.

Recent business highlights, analysts review and target price READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/arsanis-shares/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source